Regeneron Increases Stake In ISA Pharma, Plans Pivotal Study
Third Study Planned Under Clinical Collaboration
ISA Pharmaceuticals and Regeneron have updated their collaboration to outline a potential path to market for a combination of an anticancer immunotherapeutic and the checkpoint inhibitor, cemiplimab, for HPV-associated head-and-neck cancer.
